This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, M. B.
Right arrow Articles by Woods, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, M. B.
Right arrow Articles by Woods, G. L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 1999, p. 2697-2698, Vol. 37, No. 8
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Comparative Performance of the RapID Yeast Plus System and the API 20C AUX Clinical Yeast System

Michael B. Smith,* Daisy Dunklee, Hangna Vu, and Gail L. Woods

Division of Microbiology, Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555-0740

Received 10 March 1999/Returned for modification 22 April 1999/Accepted 30 April 1999

The performance of the RapID Yeast Plus System (Innovative Diagnostic Systems, Norcross, Ga.), a 4-h micropanel using single-substrate enzymatic test reactions, was compared with that of the API 20C AUX Clinical Yeast System (bioMerieux Vitek, Hazelwood, Mo.), a 48- to 72-h carbohydrate assimilation panel. Two hundred twenty-five yeasts, yeast-like fungi, and algae, comprising 28 species and including 30 isolates of Cryptococcus neoformans, an important pathogen not tested in appreciable numbers in other comparisons, were tested by both methods. On initial testing, 196 (87.1%) and 215 (95.6%) isolates were correctly identified by the RapID and API systems, respectively. Upon repeat testing, the number of correctly identified isolates increased to 220 (97.8%) for the RapID system and 223 (99.1%) for the API system. Reducing the turbidity of the test inoculum to that of a no. 3 McFarland turbidity standard, which is below that recommended by the manufacturer, resulted in the correct identification of most of the isolates initially misidentified by the RapID system, including 10 of 30 C. neoformans isolates. Concordance between the RapID and API results after repeat testing was 97.3%.


* Corresponding author. Mailing address: Division of Microbiology, Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0740. Phone: (409) 747-2484. Fax: (409) 772-5683. E-mail: mismith{at}utmb.edu.


Journal of Clinical Microbiology, August 1999, p. 2697-2698, Vol. 37, No. 8
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Sanguinetti, M., Porta, R., Sali, M., La Sorda, M., Pecorini, G., Fadda, G., Posteraro, B. (2007). Evaluation of VITEK 2 and RapID Yeast Plus Systems for Yeast Species Identification: Experience at a Large Clinical Microbiology Laboratory. J. Clin. Microbiol. 45: 1343-1346 [Abstract] [Full Text]